Probiotics for Childhood Depression: What the Null Result Means

Probiotics have not been shown to treat depression in children or adolescents. But the only meta-analysis on the question did not actually test probiotics in children with diagnosed depression, so its null result cannot settle whether the treatment works for that group.

The 2024 Chen et al. meta-analysis pooled five randomized controlled trials involving 692 participants and found a standardized mean difference (SMD) of 0.04 for depressive-symptom scores, with p=0.84. That is essentially no average difference between probiotic and comparison groups, and it was not statistically significant. The review also reported high inconsistency between trials (I²=77%).

The headline should therefore be precise: probiotics have no demonstrated antidepressant benefit for children, because no trial has tested them as an antidepressant treatment in a pediatric depression population. "No demonstrated benefit" is not the same claim as "proven ineffective."

The pooled result answers a weaker question

Chen and colleagues searched major medical databases and ClinicalTrials.gov through May 2, 2024. They found five eligible randomized trials. None enrolled children or adolescents with major depressive disorder, or another primary diagnosis of depression.

Instead, the trials enrolled highly different populations:

• Children with autism spectrum disorder in Taiwan, with a mean age of 4.82 years, received a single Lactobacillus plantarum strain; the CBCL anxious/depressed subscale was a secondary outcome.
• Children with ADHD in Iran received a multi-strain regimen for eight weeks; depression was also a secondary endpoint.
• A Taiwanese Tourette syndrome cohort received a single-strain probiotic, again with depression assessed secondarily.
• Two trials enrolled healthy children without psychiatric diagnoses.
• One healthy Indonesian sample included children aged 1 to 6 who received Lactobacillus reuteri; investigators assessed the Children's Depression Inventory at a 10-year follow-up.

Those are not interchangeable clinical settings. A probiotic given to a preschooler with autism, a school-age child with ADHD, and a healthy child cannot reasonably be assumed to target the same depressive illness—or even the same underlying symptom construct. Pooling them produces a number, but not necessarily an answer to a clinically useful question.

Every included trial treated depression as a secondary outcome. None was designed with enough statistical power to detect an antidepressant effect. The published summary provides the pooled SMD and p value, but not a confidence interval for that estimate. The p value tells us the pooled analysis did not detect a difference; it does not turn this collection of secondary outcomes into a direct trial of treatment for pediatric depression.

High heterogeneity is a warning, not background noise

An I² of 77% across five trials means the study results varied substantially. With so few trials, that variation cannot be cleanly explained away. The participants ranged from infancy through late adolescence, formulations included single strains and multi-strain blends, and treatment durations ranged from 8 to 104 weeks.

The endpoints also deserve scrutiny. Three trials reported ages, with a mean of 7.33 years. Depression instruments such as the Children's Depression Inventory and the CBCL anxious/depressed subscale have less-established psychometric performance in children younger than 8. In a trial enrolling children ages 1 to 6, a depression score may capture a very different phenomenon than it would in an adolescent with clinically diagnosed major depression.

The Indonesian study poses an additional causal problem. Measuring a depression inventory 10 years after early-childhood probiotic exposure leaves diet, family circumstances, development, school, illness, and many other influences between treatment and outcome. A decade is enough time for a child to become a teenager; it is not a credible window for assigning a later depression score to an earlier probiotic course.

The SMD of 0.04 is a valid summary of these five studies. It is not a valid estimate of probiotic efficacy for children with diagnosed depression, because none of the studies enrolled that population.

Adult studies create a hypothesis, not a pediatric recommendation

The adult literature is more developed because researchers have actually enrolled adults with clinical depression. A 2024 network meta-analysis by Yang et al. evaluated probiotic combinations for depression, anxiety, and stress in adults and identified multi-strain combinations with favorable depression results. A separate 2024 network meta-analysis by Zhao et al. compared probiotics with antidepressants in adults with major depressive disorder.

Those analyses support continued research; they do not establish that probiotics are a replacement for standard depression care. The available abstracts do not provide enough pooled effect-size detail for a responsible numerical comparison with the pediatric SMD of 0.04.

Trial design makes the contrast sharper. In a 2023 randomized clinical trial by Nikolova et al., adults with diagnosed depression received probiotics as adjunctive treatment. A separate eight-week double-blind, placebo-controlled trial tested L. plantarum PS128 in adults with major depressive disorder, reported in Lin et al. (2024). The pediatric autism trial in Chen's review used the same species, L. plantarum, but species identity does not establish that the formulation, dose, host response, or clinical effect will match across ages and diagnoses.

Even adult evidence changes with the population. A 2026 meta-analysis of healthy working adults found limited mental-health effects from probiotics in people without psychiatric diagnoses. A 2023 meta-analysis in pregnant and lactating women found mixed effects on depression and anxiety symptoms. These findings do not disprove an effect in adult major depressive disorder, but they show why a result from one population cannot be casually exported to another.

Biology offers reasons to study the question, not reasons to prescribe

Probiotics could plausibly affect mood through gut-barrier function, immune signaling, HPA-axis activity, tryptophan metabolism, or vagal pathways. A 2025 mechanistic review describes these proposed routes. Plausibility, however, is not clinical proof. No supplied pediatric depression trial has shown that changing one of these pathways reduces depressive symptoms.

Development complicates extrapolation. A 2024 umbrella review of pediatric microbiome research found that the gut microbiome continues to change through adolescence and that pediatric psychiatric microbiome profiles differ from adult profiles. Immune development, microbial colonization stability, and stress-system responsiveness also differ across childhood. A treatment that helps a subset of adults may do nothing in a developing microbiome—or may need a different strain, dose, duration, or target age.

What parents and clinicians should do now

A probiotic should not be presented as an evidence-based treatment for a depressed child or adolescent. Current research has neither validated nor directly refuted that use. The right response to a child's depressive symptoms is a clinical assessment and evidence-based care, not a supplement experiment standing in for treatment.

For researchers, the next study is obvious: enroll adolescents with diagnosed major depressive disorder, define a depression outcome as the primary endpoint, use a prespecified probiotic formulation, and power the trial for a clinically meaningful difference. Until that happens, the Chen meta-analysis remains useful mainly for identifying the gap. Its near-zero pooled estimate describes studies that missed the population most in need of an answer.